Admin Reporter- POOJA1

Nov 19 2020

Court rejects AstraZeneca’s plea on diabetes drug patent

Thursday, 19 November 2020

The Delhi high court has rejected global pharma major AstraZeneca’s application seeking a restraining order against marketing of a blockbuster anti-diabetes drug Dapagliflozin by domestic companies, including Torrent, USV, Micro Labs, Eris LifeSciences and Zydus, thus paving the way for affordable diabetes drugs in the Indian market.





With nearly a dozen companies launching generic versions at competitive prices, the stage is set for a price war between the players to get a slice of the growing Rs 15,000-crore diabetes market. AstraZeneca had sued several generic companies for the infringement of patents covering Dapagliflozin.

instagram imagesfollow us @ instagram